TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference

Rhea-AI Summary

TuHURA Biosciences (NASDAQ:HURA), a Phase 3 immune-oncology company focused on developing cancer immunotherapy resistance treatments, will participate in the 27th Annual H.C. Wainwright Global Investment Conference in New York City.

The company's President and CEO, Dr. James Bianco, will present on September 8, 2025, at 2:30 PM ET. The presentation will provide a company overview, and management will be available for one-on-one meetings. A replay will be accessible on the company's investor relations website.

TAMPA, Fla., Aug. 20, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that management will present at the 27^th Annual H.C. Wainwright Global Investment Conference taking place September 8-10, 2025 in New York City.

James Bianco, M.D., President and Chief Executive Officer of TuHURA Biosciences, is scheduled to present an overview and will be available for one-on-one meetings, as follows:

27th Annual H.C. Wainwright Global Investment Conference
Date:	Monday, September 8, 2025
Time:	2:30 PM Eastern Time
Link:	Click Here

A replay of the presentation will be available on the Events page of the Investors section of the Company's website (tuhurabio.com). For more information about the event, please visit the conference website.

About TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 immuno-oncology company developing novel therapies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of patients with cancer.

In addition to its innate immune agonist product candidates, TuHURA acquired TBS-2025 in the merger with Kineta on June 30, 2025. TBS-2025 is a VISTA inhibiting mAb asset moving into Phase 2 development in mutNPM1 r/r AML. In addition, TuHURA is leveraging its Delta Opiod Receptor technology to develop first-in-class, bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

For more information, please visit www.tuhurabio.com and connect with TuHURA on Facebook, X, and LinkedIn.

Investor Contact:
Monique Kosse
Gilmartin Group
Monique@GilmartinIR.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/tuhura-biosciences-inc-to-present-at-the-27th-annual-hc-wainwright-global-investment-conference-302533745.html

SOURCE TuHURA Biosciences, Inc.

FAQ

When is TuHURA Biosciences (HURA) presenting at the H.C. Wainwright Conference?

TuHURA Biosciences will present on Monday, September 8, 2025 at 2:30 PM Eastern Time at the H.C. Wainwright Global Investment Conference in New York City.

Who will present for TuHURA Biosciences at the H.C. Wainwright Conference?

Dr. James Bianco, President and Chief Executive Officer of TuHURA Biosciences, will present the company overview.

What stage is TuHURA Biosciences' cancer immunotherapy development?

TuHURA Biosciences is a Phase 3 immune-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy.

How can investors access TuHURA's H.C. Wainwright Conference presentation?

A replay of the presentation will be available on the Events page of the Investors section of TuHURA's website (tuhurabio.com).